HC Wainwright Analysts Boost Earnings Estimates for ORKA

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) - Stock analysts at HC Wainwright boosted their Q2 2025 earnings per share estimates for Oruka Therapeutics in a note issued to investors on Tuesday, May 27th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($0.47) per share for the quarter, up from their previous estimate of ($0.49). HC Wainwright has a "Buy" rating and a $45.00 price objective on the stock. The consensus estimate for Oruka Therapeutics' current full-year earnings is ($3.41) per share. HC Wainwright also issued estimates for Oruka Therapeutics' Q3 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($2.11) EPS, Q1 2026 earnings at ($0.64) EPS, Q3 2026 earnings at ($0.71) EPS and FY2026 earnings at ($2.76) EPS.

ORKA has been the topic of several other reports. BTIG Research assumed coverage on Oruka Therapeutics in a research note on Thursday, May 22nd. They issued a "buy" rating on the stock. Wolfe Research assumed coverage on Oruka Therapeutics in a research note on Tuesday, February 4th. They issued an "outperform" rating and a $20.00 price objective on the stock. Wedbush reaffirmed an "outperform" rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a research note on Thursday, May 15th. Finally, Wall Street Zen upgraded Oruka Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $40.38.

Oruka Therapeutics Stock Up 4.9%

Shares of NASDAQ ORKA traded up $0.54 during midday trading on Thursday, hitting $11.50. The stock had a trading volume of 114,538 shares, compared to its average volume of 224,620. The company has a market capitalization of $430.57 million, a price-to-earnings ratio of -1.84 and a beta of 0.25. Oruka Therapeutics has a 1-year low of $5.49 and a 1-year high of $31.13. The company has a fifty day moving average price of $9.73 and a 200 day moving average price of $13.61.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.57) by $0.17.

Institutional Investors Weigh In On Oruka Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. purchased a new stake in Oruka Therapeutics during the 4th quarter worth approximately $54,000. AlphaCentric Advisors LLC purchased a new stake in Oruka Therapeutics during the 4th quarter worth approximately $119,000. China Universal Asset Management Co. Ltd. purchased a new stake in Oruka Therapeutics during the 4th quarter worth approximately $144,000. AlphaQuest LLC purchased a new stake in Oruka Therapeutics during the 1st quarter worth approximately $168,000. Finally, Cannon Global Investment Management LLC bought a new stake in shares of Oruka Therapeutics in the 1st quarter valued at approximately $195,000. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.